Valuation: Genix Pharmaceuticals Corporation

Market Cap 918K 655K 573K 528K 487K 63.05M 939K 6.32M 2.48M 30.89M 2.46M 2.41M 106M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 1.92M 1.37M 1.2M 1.1M 1.02M 132M 1.96M 13.19M 5.17M 64.49M 5.14M 5.02M 222M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
3 months-25.00%
6 months-40.00%
Current year-40.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.04
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.2
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 2018-08-02
President - 2021-05-20
Director of Finance/CFO - 2020-12-13
Director TitleAgeSince
Director/Board Member 57 2018-08-02
Director/Board Member 76 2019-03-10
Director/Board Member 44 2019-09-04
Date Insider Type Main position Quantity % Market Cap.
9/9/25 Other

Chief Executive Officer

0 0%
9/9/25 Option

Chairman

1,000,000 1.6885%
9/9/25 Option

Chief Executive Officer

1,000,000 1.6885%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-78.57% 654K
-0.90%-0.31%+13.62%+80.12% 48.56B
-0.23%-0.63%+67.00%+115.81% 35.65B
-0.76%-1.57%-3.87%+37.62% 11.98B
-0.88%-1.32%+18.04%+92.11% 11.95B
0.00%+1.90%+34.67%+129.06% 9.29B
-0.75%-0.17%+18.85%+36.91% 6.95B
+3.37%-0.96%+46.11%-4.38% 6.79B
-2.25%-1.40%+1.39%+218.40% 6.7B
-9.93%+5.82%-22.89%+16.29% 6.81B
Average -1.23%+0.51%+12.29%+64.34% 14.47B
Weighted average by Cap. -0.94%+0.33%+26.53%+86.88%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.47 -
Net income -73.2K -52.17K -45.65K -42.09K -38.81K -5.03M -74.84K -503K -198K -2.46M -196K -192K -8.48M -335K -239K -209K -193K -178K -23M -343K -2.3M -904K -11.27M -898K -878K -38.8M
Net Debt 804K 573K 502K 462K 426K 55.21M 822K 5.53M 2.17M 27.05M 2.15M 2.11M 93.12M 999K 712K 623K 575K 530K 68.61M 1.02M 6.87M 2.7M 33.61M 2.68M 2.62M 116M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
  1. Stock Market
  2. Stocks
  3. GENX Stock